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Fungi are an important cause of infection in patients
undergoing solid organ transplantation and bone marrow
or hematopoietic stem cell transplantation (BMT/HSCT).
The incidence and mortality of fungal infections differ
according to the organ and the time since transplantation. In
the first 30 days after transplantation, yeast (primarily
Candida spp.) predominate. After the first month, filamen-
tous fungi, such as Aspergillus spp., are the most frequent
agents of infection (1-6).
In BMT/HSCT patients, however, invasive aspergillosis
has two peaks of incidence: one at one month post-
transplantation and another approximately 90 days after
the transplant if the patient develops chronic graft versus
host disease (7,8).
Among solid organ transplantation, liver and lung
transplant have the highest risk for fungal infection due to
underlying diseases, surgical techniques and the graft itself
(4,9).
Antifungal prophylaxis use is well established following
some transplant types, such as BMT/HSCT and liver
(10,11). However, few studies have evaluated heart and
pancreas transplants. One of the major challenges is the
prevention of filamentous fungal infections, especially by
Aspergillus spp., in high-risk patients, such as those who
have undergone an allogeneic BMT and developed chronic
graft versus host disease or undergone a lung transplanta-
tion (12,13).
To standardize the use of primary prophylaxis in
transplant patients, we analyzed the literature related to
the following transplants: liver, kidney, heart, lung, and
HSCT. The IDSA (Infectious Diseases Society of America)
system was used to determine the levels of evidence.
Recommendations
1. Liver transplantation (11,14-20)
Universal prophylaxis: no (CII)
Targeted prophylaxis: yes (AI)
- Fluconazole 400 mg/day for 21 days
N Criterion 1 – at least one of the following risk factors:
fulminant hepatitis, re-transplant requirement, post-tx
hemodialysis, or the use of antibodies for rejection
treatment.
N Criterion 2 – at least two of the following risk factors:
antibiotic prophylaxis for spontaneous bacterial peri-
tonitis (SBP) pre-tx, reoperation, ICU admission in the
30 days before the tx, or antibiotic use in the 30 days
before the tx.
2. Kidney transplantation
There are no studies on prophylaxis.
Prophylaxis is not recommended (DII).
3. Lung transplantation (12,21-24)
Universal prophylaxis: yes (AI)
- Inhaled amphotericin B deoxycholate for 3 months
(50 mg + 50 ml of distilled water; 10 ml inhalation twice a
day)
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Targeted prophylaxis: yes, if the recipient or donor has
airway colonization by Aspergillus spp. pre-tx or post-tx
(associated with amphotericin B inhalation).
First choice*: 400 mg itraconazole orally for 3 months
(BIII)
Second choice: IV voriconazole (6 mg/kg/day) or oral
voriconazole (400 mg/day) for 3 months (CIII)
* Advised serum concentration.
4. Heart transplantation (22)
Prophylaxis not indicated (DII).
5. Hematopoietic stem cell transplant (HSCT)(10,25-28)
Universal prophylaxis: yes (AI)
Fluconazole 400 mg/day IV or oral for 100 days
Targeted prophylaxis: yes, for patients under treatment
for GVHD
First option: amphotericin B deoxycholate 1 mg/kg/day
(or equivalent doses of a lipidic formulation) for 100 days
(CIII)
Second option: itraconazole* 400 mg/day, oral for 100
days (CIII)
Third option: EV voriconazole (6 mg/kg/day) or oral
voriconazole (400 mg/day) for 100 days (CIII)
** Advised serum concentration.
Controlled and randomized studies have been registered
with other azoles, but they were not standardized in the
institution or perhaps they are not available in Brazil.
6. Pancreas transplant (29)
Universal prophylaxis: yes (CII)
Fluconazole 400 mg/day IV or VO for 7 days (surgical
prophylaxis)
Targeted prophylaxis: no (DII)
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APPENDIX
PROFILAXIA DAS INFECc¸O˜ES FU´NGICAS EM
PACIENTES TRANSPLANTADOS
Os fungos sa˜o uma importante causa de infecc¸a˜o nos
pacientes submetidos a transplante de o´rga˜o so´lido e
medula o´ssea ou transplante de ce´lulas tronco hemato-
poie´ticas (TMO/TCTH). A incideˆncia e a letalidade das
infecc¸o˜es fu´ngicas variam, entretanto, de acordo com o tipo
de transplante e do perı´odo apo´s o transplante. Nos
primeiros 30 dias ocorre o predomı´nio das leveduras
particurlamente Candida spp. Apo´s o primeiro meˆs pre-
dominam os fungos filamentosos como Aspergillus spp (1-
6). Nos pacientes submetidos a TMO/TCTH, entretanto, a
Aspergilose invasiva apresenta dois picos de incideˆncia um
no final do primeiro meˆs e outro aproximadamente 90 dias
depois do transplante caso o paciente desenvolva doenc¸a
do enxerto versus o hospedeiro (7-8). Dentre os trans-
plantes de o´rga˜o so´lidos os que apresentam maior risco
para o desenvolvimento de infecc¸o˜es fu´ngicas sa˜o o
transplante de fı´gado e de pulma˜o, por questo˜es ligadas
a`s pro´prias doenc¸as de base, te´cnica ciru´rgica e enxerto
(4,9).
O uso de profilaxia antifu´ngica ja´ esta bem consolidada
para alguns grupos de transplantes como TMO/TCTH e
transplantes hepa´ticos (10,11). Contudo, ainda ha´ uma
escassez de estudo em transplante de corac¸a˜o e paˆncreas.
O grande dilema, entretanto, e´ a prevenc¸a˜o de infecc¸o˜es por
fungos filamentosos em especial Aspergillus spp nos
pacientes de alto risco como transplante de medula o´ssea
alogeˆnico com doenc¸a do enxerto contra o hospedeiro
(DECH) e transplantados de pulma˜o (12,13).
Com intuito de padronizar o uso de profilaxia prima´ria
em pacientes transplantados, foi analisada a literatura
referente aos seguintes transplantes: fı´gado, rim, corac¸a˜o,
pulma˜o e TCTH. Para a determinac¸a˜o dos nı´veis de
evideˆncia foi utilizado o sistema da IDSA (Infectious
Diseases Society of America).
Recomendac¸o˜es:
1. Transplante de Fı´gado (11,14-20)
Profilaxia universal: na˜o (CII)
Profilaxia dirigida: sim (AI)
- Fluconazol 400 mg/dia por 21 dias
N Crite´rio 1 – pelo menos um dos seguintes fatores de
risco: hepatite fulminante, re-transplante, hemodia´lise
po´s-transplante, uso de anticorpos para tratamento de
rejeic¸a˜o.
N Crite´rio 2 – pelo menos dois dos seguintes fatores de
risco: uso de antibio´tico profila´tico para peritonite
bacteriana espontaˆnea pre´-transplante, reoperac¸a˜o,
admissa˜o em unidade de terapia intensiva nos u´ltimos
30 dias antes do transplante, antibio´ticos nos u´ltimos
30 dias antes do transplante.
2. Transplante de Rim
Na˜o ha´ estudos sobre profilaxia
Profilaxia na˜o indicada (DII)
3. Transplante de Pulma˜o (12,21-24)
Profilaxia universal: sim (AI)
Anfotericina B deoxicolato via inalato´ria, por 3 meses
(50 mg + 50 ml de a´gua destilada – inalac¸a˜o com 10 ml, 2
vezes por dia)
Profilaxia dirigida: sim, se receptor ou doador com
colonizac¸a˜o das vias ae´reas por Aspergillus spp pre´-tx ou
po´s-tx (associada a` anfotericina B inalato´ria)
Primeira opc¸a˜o: Itraconazol* 400 mg oral por 3 meses
(BIII)
Tabela 1 - Incideˆncia e mortalidade das Infecc¸o˜es Fu´ngicas
na populac¸a˜o de pacientes submetidos a transplante de







TCTH 3,9% (AI) 50%
NR: na˜o relatado.
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Segunda opc¸a˜o: Voriconazol EV (6 mg/kg/dia)/Oral
(400 mg/dia) por 3 meses (CIII)
*Aconselha´vel dosagem se´rica.
4. Transplante de Corac¸a˜o (22)
Profilaxia na˜o indicada (DII)
5. Transplante de Ce´lulas TroncoHematopoe´ticas (10,25-28)
Profilaxia universal: sim (AI)
Fluconazol 400 mg/dia EV/Oral por 100 dias
Profilaxia dirigida: sim, para pacientes sob tratamento
para DECH.
Primeira opc¸a˜o: Anfotericina B deoxicolato 1 mg/kg/dia
(ou doses equivalentes de formulac¸o˜es lipı´dicas) por 100
dias (CIII)
Segunda opc¸a˜o: Itraconazol* oral 400 mg/dia por 100 dias
(CIII)
Terceira opc¸a˜o Voriconazol: EV (6 mg/kg/dia)/Oral
(400 mg/dia) por 100 dias (CIII)
*Aconselha´vel dosagem se´rica
Obs. Ha´ estudos controlados e randomizados com
outros azo´licos, pore´m na˜o sa˜o medicamentos padroni-
zados na instituic¸a˜o ou talvez na˜o disponı´veis no
Brasil.
6. Transplante de Paˆncreas (29)
Profilaxia universal: sim (CII)
Fluconazol 400 mg/dia EV/VO por 7 dias (profilaxia
ciru´rgica)
Profilaxia dirigida: na˜o (DII)
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